These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 33389934)

  • 21. OCTA changes following loading phase with intravitreal aflibercept for DME.
    Kansal V; Colleaux K; Rawlings N
    Can J Ophthalmol; 2023 Oct; 58(5):480-490. PubMed ID: 35526615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.
    Mori K; Yoshida S; Kobayashi Y; Ishikawa K; Nakao S; Hisatomi T; Haruta M; Isihibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):735-741. PubMed ID: 31960130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study.
    Fan W; Uji A; Wang K; Falavarjani KG; Wykoff CC; Brown DM; Van Hemert J; Sagong M; Sadda SR; Ip M
    Retina; 2020 Jun; 40(6):1029-1037. PubMed ID: 31356494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
    Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
    Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optical Coherence Tomography Angiography in Diabetic Macular Edema Treated with Intravitreal Aflibercept: A 48-Week Observational Study (the DOCTA Study).
    Korobelnik JF; Gaucher D; Baillif S; Creuzot-Garcher C; Kodjikian L; Weber M
    Ophthalmologica; 2023; 246(2):71-80. PubMed ID: 36646050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
    Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OCT Angiography Study of the Macula in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept.
    Dastiridou A; Karathanou K; Riga P; Anagnostopoulou S; Balasubramanian S; Mataftsi A; Brazitikos P; Ziakas N; Androudi S
    Ocul Immunol Inflamm; 2021 Jul; 29(5):926-931. PubMed ID: 31951761
    [No Abstract]   [Full Text] [Related]  

  • 28. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
    Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting visual outcomes following anti-vascular endothelial growth factor treatment for diabetic macular edema.
    Rana V; Agarwal A; Arora A; Bansal R; Dogra M; Bhadada SK; Singh N; Gupta V
    Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S16-S21. PubMed ID: 38131536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of optical coherence tomography angiography in the assessment of diabetic macular edema staging and laser photocoagulation efficacy.
    Fu WN; Du Y; Gong ZY
    Photodiagnosis Photodyn Ther; 2024 Apr; 46():104055. PubMed ID: 38508440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOVEAL MÜLLER CELL CONE AS A PROGNOSTIC OPTICAL COHERENCE TOMOGRAPHY BIOMARKER FOR INITIAL RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN CYSTOID DIABETIC MACULAR EDEMA.
    Choi M; Yun C; Oh JH; Kim SW
    Retina; 2022 Jan; 42(1):129-137. PubMed ID: 34334704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Features Related to OCT Angiography Artifacts in Patients with Diabetic Macular Edema.
    Tamer Kaderli S; Piccoli G; Limoli C; Ginelli S; Caboni S; Brotto L; Torti E; O'Toole L; Nucci P; Vujosevic S
    Ophthalmol Retina; 2024 Aug; 8(8):813-822. PubMed ID: 38447922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASSOCIATION OF SERUM VASOGENIC AND PROINFLAMMATORY FACTORS WITH CLINICAL RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR DIABETIC MACULAR EDEMA.
    Brito PS; Costa JV; Barbosa-Matos C; Costa SM; Correia-Pinto J; Silva RM
    Retina; 2021 Feb; 41(2):345-354. PubMed ID: 32453069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Alagorie AR; Nittala MG; Velaga S; Zhou B; Rusakevich AM; Wykoff CC; Sadda SR
    JAMA Ophthalmol; 2020 Aug; 138(8):851-857. PubMed ID: 32584384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
    Campos A; Campos EJ; do Carmo A; Patrício M; Castro de Sousa JP; Ambrósio AF; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subthreshold Photocoagulation, Laser Endpoint Management Based on Optical Coherence Tomography Angiography in Cases of Diabetic Macular Edema Refractory to Anti-VEGF.
    Karasu B; Akbas YB; Aykut A; Çelebi ARC
    Klin Monbl Augenheilkd; 2024 Feb; 241(2):197-208. PubMed ID: 35453154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy.
    Statler B; Conti TF; Conti FF; Silva FQ; Rachitskaya A; Yuan A; Schachat A; Kaiser PK; Singh RP; Babiuch A
    Ophthalmic Surg Lasers Imaging Retina; 2020 Aug; 51(8):448-455. PubMed ID: 32818277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optical coherence tomography angiography of macular telangiectasia type 1: Comparison with mild diabetic macular edema.
    Mao L; Weng SS; Gong YY; Yu SQ
    Lasers Surg Med; 2017 Mar; 49(3):225-232. PubMed ID: 28168812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of macular vascular density and foveal avascular zone changes by optical coherence tomography angiography (OCT-A) after intravitreal dexamethasone implant in diabetic macular edema resistant to Anti-VEGF treatment.
    Ceylan A; Dogan ME; Demircan A; Akar Y
    Int Ophthalmol; 2022 Nov; 42(11):3579-3588. PubMed ID: 35737210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.